203 related articles for article (PubMed ID: 34321240)
1. Mutant
Goldberg L; Negi V; Chung YJ; Onozawa M; Zhu YJ; Walker RL; Pierce R; Patel DP; Krausz KW; Gonzalez FJ; Goodell MA; Rodriguez BAT; Meltzer PS; Aplan PD
Cancer Res; 2021 Oct; 81(19):5033-5046. PubMed ID: 34321240
[TBL] [Abstract][Full Text] [Related]
2. A murine model for human early/immature T-cell precursor acute lymphoblastic leukemia (EITP ALL).
Negi V; Aplan PD
Oncoscience; 2022; 9():60-63. PubMed ID: 36330381
[TBL] [Abstract][Full Text] [Related]
3. Thymic precursor cells generate acute myeloid leukemia in NUP98-PHF23/NUP98-HOXD13 double transgenic mice.
Kundu S; Park ES; Chung YJ; Walker RL; Zhu YJ; Negi V; Meltzer PS; Aplan PD
Sci Rep; 2019 Nov; 9(1):17213. PubMed ID: 31748606
[TBL] [Abstract][Full Text] [Related]
4. A NUP98-HOXD13 fusion gene impairs differentiation of B and T lymphocytes and leads to expansion of thymocytes with partial TCRB gene rearrangement.
Choi CW; Chung YJ; Slape C; Aplan PD
J Immunol; 2009 Nov; 183(10):6227-35. PubMed ID: 19841179
[TBL] [Abstract][Full Text] [Related]
5. The NUP98-HOXD13 fusion oncogene induces thymocyte self-renewal via Lmo2/Lyl1.
Shields BJ; Slape CI; Vo N; Jackson JT; Pliego-Zamora A; Ranasinghe H; Shi W; Curtis DJ; McCormack MP
Leukemia; 2019 Aug; 33(8):1868-1880. PubMed ID: 30700838
[TBL] [Abstract][Full Text] [Related]
6. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia.
Ogawara Y; Katsumoto T; Aikawa Y; Shima Y; Kagiyama Y; Soga T; Matsunaga H; Seki T; Araki K; Kitabayashi I
Cancer Res; 2015 May; 75(10):2005-16. PubMed ID: 25795706
[TBL] [Abstract][Full Text] [Related]
7. Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation.
Slape C; Hartung H; Lin YW; Bies J; Wolff L; Aplan PD
Cancer Res; 2007 Jun; 67(11):5148-55. PubMed ID: 17545593
[TBL] [Abstract][Full Text] [Related]
8. Identification of a selective inhibitor of IDH2/R140Q enzyme that induces cellular differentiation in leukemia cells.
Chen J; Yang J; Wei Q; Weng L; Wu F; Shi Y; Cheng X; Cai X; Hu C; Cao P
Cell Commun Signal; 2020 Apr; 18(1):55. PubMed ID: 32245484
[TBL] [Abstract][Full Text] [Related]
9. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance.
Kats LM; Reschke M; Taulli R; Pozdnyakova O; Burgess K; Bhargava P; Straley K; Karnik R; Meissner A; Small D; Su SM; Yen K; Zhang J; Pandolfi PP
Cell Stem Cell; 2014 Mar; 14(3):329-41. PubMed ID: 24440599
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants.
Gao M; Zhu H; Fu L; Li Y; Bao X; Fu H; Quan H; Wang L; Lou L
Cancer Sci; 2019 Oct; 110(10):3306-3314. PubMed ID: 31361380
[TBL] [Abstract][Full Text] [Related]
11. Functional analysis of the NUP98-CCDC28A fusion protein.
Petit A; Ragu C; Soler G; Ottolenghi C; Schluth C; Radford-Weiss I; Schneider-Maunoury S; Callebaut I; Dastugue N; Drabkin HA; Bernard OA; Romana S; Penard-Lacronique V
Haematologica; 2012 Mar; 97(3):379-87. PubMed ID: 22058212
[TBL] [Abstract][Full Text] [Related]
12. Genome-scale integrated analysis to identify prospective molecular mechanisms and therapeutic targets in isocitrate dehydrogenase 2 R140Q-mutated acute myeloid leukemia.
Huang R; Liao X; Li J; Wei J; Su X; Lai X; Liu B; Zhu F; Huang Y; Li Q
Oncol Rep; 2019 May; 41(5):2876-2888. PubMed ID: 30896832
[TBL] [Abstract][Full Text] [Related]
13. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
[TBL] [Abstract][Full Text] [Related]
14. Gene expression profiling and candidate gene resequencing identifies pathways and mutations important for malignant transformation caused by leukemogenic fusion genes.
Novak RL; Harper DP; Caudell D; Slape C; Beachy SH; Aplan PD
Exp Hematol; 2012 Dec; 40(12):1016-27. PubMed ID: 22885519
[TBL] [Abstract][Full Text] [Related]
15. Hhex regulates Kit to promote radioresistance of self-renewing thymocytes in Lmo2-transgenic mice.
Shields BJ; Alserihi R; Nasa C; Bogue C; Alexander WS; McCormack MP
Leukemia; 2015 Apr; 29(4):927-38. PubMed ID: 25283843
[TBL] [Abstract][Full Text] [Related]
16. Transgenic IDH2
Wang D; Zheng L; Cheng BYL; Sin CF; Li R; Tsui SP; Yi X; Ma ACH; He BL; Leung AYH; Sun X
Oncogene; 2023 Apr; 42(16):1272-1281. PubMed ID: 36739363
[TBL] [Abstract][Full Text] [Related]
17. Mouse embryonic stem cells that express a NUP98-HOXD13 fusion protein are impaired in their ability to differentiate and can be complemented by BCR-ABL.
Slape C; Chung YJ; Soloway PD; Tessarollo L; Aplan PD
Leukemia; 2007 Jun; 21(6):1239-48. PubMed ID: 17377591
[TBL] [Abstract][Full Text] [Related]
18. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
19. Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL.
Simonin M; Schmidt A; Bontoux C; Dourthe MÉ; Lengliné E; Andrieu GP; Lhermitte L; Graux C; Grardel N; Cayuela JM; Huguet F; Arnoux I; Ducassou S; Macintyre E; Gandemer V; Dombret H; Petit A; Ifrah N; Baruchel A; Boissel N; Asnafi V
J Hematol Oncol; 2021 May; 14(1):74. PubMed ID: 33941203
[TBL] [Abstract][Full Text] [Related]
20. Knock-in of a FLT3/ITD mutation cooperates with a NUP98-HOXD13 fusion to generate acute myeloid leukemia in a mouse model.
Greenblatt S; Li L; Slape C; Nguyen B; Novak R; Duffield A; Huso D; Desiderio S; Borowitz MJ; Aplan P; Small D
Blood; 2012 Mar; 119(12):2883-94. PubMed ID: 22323452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]